Vitamin D Endocrine System and COVID-19

dc.contributor.authorBouillon, Roger
dc.contributor.authorManuel Quesada-Gomez, Jose
dc.contributor.authoraffiliation[Bouillon, Roger] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, Dept Chron Dis Metab & Ageing, B-3000 Leuven, Belgium
dc.contributor.authoraffiliation[Manuel Quesada-Gomez, Jose] Univ Cordoba, Hosp Univ Reina Sofia, Fdn Progreso & Salud, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain
dc.contributor.authoraffiliation[Manuel Quesada-Gomez, Jose] CIBER Fragilidad & Envejecimiento Saludable CIBER, Madrid, Spain
dc.date.accessioned2025-01-07T13:24:28Z
dc.date.available2025-01-07T13:24:28Z
dc.date.issued2021-11-17
dc.description.abstractPreclinical data strongly suggest that the vitamin D endocrine system (VDES) may have extraskeletal effects. Cells of the immune and cardiovascular systems and lungs can express the vitamin D receptor, and overall these cells respond in a coherent fashion when exposed to 1,25-dihydroxyvitamin D, the main metabolite of the VDES. Supplementation of vitamin D-deficient subjects may decrease the risk of upper respiratory infections. The VDES also has broad anti-inflammatory and anti-thrombotic effects, and other mechanisms argue for a potential beneficial effect of a good vitamin D status on acute respiratory distress syndrome, a major complication of this SARS-2/COVID-19 infection. Activation of the VDES may thus have beneficial effects on the severity of COVID-19. Meta-analysis of observational data show that a better vitamin D status decreased the requirement of intensive care treatment or decreased mortality. A pilot study in Cordoba indicated that admission to intensive care was drastically reduced by administration of a high dose of calcifediol early after hospital admission for COVID-19. A large observational study in Barcelona confirmed that such therapy significantly decreased the odds ratio (OR) of mortality (OR = 0.52). This was also the conclusion of a retrospective study in five hospitals of Southern Spain. A retrospective study on all Andalusian patients hospitalized because of COVID-19, based on real-world data from the health care system, concluded that prescription of calcifediol (hazard ratio [HR] = 0.67) or vitamin D (HR = 0.75), 15 days before hospital admission decreased mortality within the first month. In conclusion, a good vitamin D status may have beneficial effects on the course of COVID-19. This needs to be confirmed by large, randomized trials, but in the meantime, we recommend (rapid) correction of 25 hydroxyvitamin D (25OHD) deficiency in subjects exposed to this coronavirus. (c) 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
dc.identifier.doi10.1002/jbm4.10576
dc.identifier.essn2473-4039
dc.identifier.pmid34950831
dc.identifier.unpaywallURLhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jbm4.10576
dc.identifier.urihttps://hdl.handle.net/10668/25486
dc.identifier.wosID719677700001
dc.issue.number12
dc.journal.titleJbmr plus
dc.journal.titleabbreviationJbmr plus
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.publisherWiley
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectVITAMIN D
dc.subjectCALCIFEDIOL
dc.subjectCOVID-19
dc.subjectMORTALITY
dc.subjectACUTE RESPIRATORY DISTRESS SYNDROME
dc.subjectINTENSIVE CARE TREATMENT
dc.subjectRenin-angiotensin system
dc.subjectAcute lung injury
dc.subjectD-receptor
dc.subject1,25-dihydroxyvitamin d-3
dc.subjectTissue factor
dc.subjectD supplementation
dc.subjectImmune regulation
dc.subjectD deficiency
dc.subjectExpression
dc.subjectCells
dc.titleVitamin D Endocrine System and COVID-19
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number5
dc.wostypeArticle

Files